AURELIA ONLINE / マンジャロのやめ方
How to Stop Mounjaro: Is Dosing Every 2 or 3 Weeks Medically Appropriate?
Evidence-based guidance on stopping tirzepatide, reducing the dose, extending the dosing interval, weight regain, blood glucose changes, and restarting treatment.
Key points
- The approved standard schedule for Mounjaro is once weekly. Planned dosing every two or three weeks is not the standard approved regimen.
- Limited modeling studies, case reports, and small observational studies suggest that less-frequent dosing may maintain part of the weight-loss effect in selected patients, but this has not been established as a routine method.
- Mounjaro does not generally require tapering to prevent a classic physical withdrawal syndrome. The main concern is return of appetite, weight regain, and worsening glucose control.
Key conclusion
- The approved standard schedule for Mounjaro is once weekly. Planned dosing every two or three weeks is not the standard approved regimen.
- Limited modeling studies, case reports, and small observational studies suggest that less-frequent dosing may maintain part of the weight-loss effect in selected patients, but this has not been established as a routine method.
- Mounjaro does not generally require tapering to prevent a classic physical withdrawal syndrome. The main concern is return of appetite, weight regain, and worsening glucose control.
Why two- or three-week dosing is different
- Tirzepatide has an elimination half-life of about five days. After 14 or 21 days, drug exposure is substantially lower than with weekly dosing, so appetite control and adverse effects may fluctuate more.
- Accidentally missing one dose is not the same as intentionally changing to a long-term two- or three-week schedule.
Options after reaching the target weight
- Continue the same weekly dose if benefits outweigh adverse effects and cost.
- Reduce from 7.5 mg to 5 mg, or from 5 mg to 2.5 mg, while keeping weekly dosing.
- Consider complete discontinuation with a monitoring plan for weight, appetite, waist circumference, and glucose.
- Do not restart a previous high dose after a long interruption without medical review.
Weight regain after stopping
- In SURMOUNT-4, participants who stopped tirzepatide regained substantial weight, while those who continued treatment maintained or extended their weight loss.
- Regain is not simply a failure of willpower. Biological changes after weight loss can increase hunger and reduce energy expenditure.
Frequently asked questions
Key conclusion?
The approved standard schedule for Mounjaro is once weekly. Planned dosing every two or three weeks is not the standard approved regimen. Limited modeling studies, case reports, and small observational studies suggest that less-frequent dosing may maintain part of the weight-loss effect in selected patients, but this has not been established as a routine method. Mounjaro does not generally require tapering to prevent a classic physical withdrawal syndrome. The main concern is return of appetite, weight regain, and worsening glucose control.
Why two- or three-week dosing is different?
Tirzepatide has an elimination half-life of about five days. After 14 or 21 days, drug exposure is substantially lower than with weekly dosing, so appetite control and adverse effects may fluctuate more. Accidentally missing one dose is not the same as intentionally changing to a long-term two- or three-week schedule.
Options after reaching the target weight?
Continue the same weekly dose if benefits outweigh adverse effects and cost. Reduce from 7.5 mg to 5 mg, or from 5 mg to 2.5 mg, while keeping weekly dosing. Consider complete discontinuation with a monitoring plan for weight, appetite, waist circumference, and glucose. Do not restart a previous high dose after a long interruption without medical review.
References
Related pages
Book an online consultationThis page provides general medical information and does not replace individual diagnosis or treatment. In Japan, Mounjaro is approved for type 2 diabetes; use for weight management is off-label. Dose changes must be decided after medical review.